The Interministerial Commission on Medicines Prices (CIPM) has agreed at this week’s meeting to finance, within the National Health System (NHS), two medicines for metastatic breast cancer, Enhertu® and Trodelvy®.

TDB keeps you informed. Follow us on Facebook, Twitter and Instagram.

It is estimated that around 2,000 women will benefit each year from treatments with Enhertu® or Trodelvy®, following the agreement of the CIPM, made up of representatives from several Ministries and all the Autonomous Communities. Active ingredients of Enhertu® and Trodelvy® The first drug, Enhertu®, contains the active ingredient trastuzumab deruxtecan and is indicated for HER2-positive unresectable or metastatic breast cancer that has received one or more previous HER2-targeted regimens. Trodelvy® contains the active substance sacituzumab govitecan and is indicated for the treatment of patients with unresectable or metastatic triple-negative breast cancer who have received two or more prior systemic treatments, including at least one for advanced disease.

Since their authorisation, both medicines have been accessible through the medicines access programmes in special situations, managed by the Spanish Medicines and Health Products Agency (AEMPS). The CIPM agreement opens the door to the incorporation of these two medicines into the NHS pharmaceutical provision as soon as the agreement is formalised and included in the nomenclature, in early December. Breast cancer is the most common tumour in women and the leading cause of cancer-related death in this group. By 2022, the incidence of breast cancer is estimated at 34,000 new cases and more than 6,600 deaths, mainly due to disease progression.